ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the mechanism of action of imatinib and its clinical efficacy have been well established, little is known about mechanisms underlying changes in energy metabolism of BCR-ABL driven CML cells in response to imatinib.